Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) and Forte Biosciences (NASDAQ:FBRX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.
Institutional & Insider Ownership
99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Phathom Pharmaceuticals and Forte Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Phathom Pharmaceuticals | -76.77% | N/A | -44.29% |
| Forte Biosciences | N/A | -106.17% | -85.50% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Phathom Pharmaceuticals | 1 | 0 | 5 | 1 | 2.86 |
| Forte Biosciences | 1 | 0 | 3 | 0 | 2.50 |
Phathom Pharmaceuticals currently has a consensus price target of $24.50, indicating a potential upside of 128.76%. Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 271.19%. Given Forte Biosciences’ higher possible upside, analysts plainly believe Forte Biosciences is more favorable than Phathom Pharmaceuticals.
Risk and Volatility
Phathom Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500.
Valuation & Earnings
This table compares Phathom Pharmaceuticals and Forte Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Phathom Pharmaceuticals | $175.11 million | 4.88 | -$221.25 million | ($2.12) | -5.05 |
| Forte Biosciences | N/A | N/A | -$69.38 million | ($4.64) | -3.89 |
Forte Biosciences has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Phathom Pharmaceuticals beats Forte Biosciences on 9 of the 14 factors compared between the two stocks.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
About Forte Biosciences
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
